pipeline-prospector-insert-v1
X

Find Oncology Drugs in Phase II Clinical Development in GERMANY

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AMG510

            Therapeutic Area: Oncology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Amgen

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 13, 2020

            Details:

            QIAGEN and Amgen to develop tissue-based therascreen® test, paired with investigational treatment AMG 510, to identify patients whose cancers have KRAS G12C mutation.